I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 52 000 VND -0.76% Market Closed
Market Cap: 8T VND
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-11%
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

IMP Price Targets Summary
Imexpharm Corp

Wall Street analysts forecast IMP stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMP is 46 308 VND with a low forecast of 45 248 VND and a high forecast of 48 300 VND.

IMP Lowest Forecast
Wall Street Target
45 248 VND
13% Downside
IMP Average Forecast
Wall Street Target
46 308 VND
11% Downside
IMP Highest Forecast
Wall Street Target
48 300 VND
7% Downside
Lowest
Price Target
45 248 VND
13% Downside
Average
Price Target
46 308 VND
11% Downside
Highest
Price Target
48 300 VND
7% Downside
Imexpharm Corp Competitors:
Price Targets
4569
Kyorin Holdings Inc
1% Upside
PHO
Photocure ASA
65% Upside
SUVENPHAR
Suven Pharmaceuticals Ltd
36% Upside
F
FAE
Faes Farma SA
7% Upside
4569
Kyorin Holdings Inc
1% Upside
PHO
Photocure ASA
65% Upside
SUVENPHAR
Suven Pharmaceuticals Ltd
36% Upside
F
FAE
Faes Farma SA
7% Upside
B
053030
Binex Co Ltd
87% Upside
4503
Astellas Pharma Inc
27% Upside
M
600993
Mayinglong Pharmaceutical Group Co Ltd
33% Upside
E
ENZY
Enzymatica AB (publ)
9% Downside

Revenue
Forecast

Revenue Estimate
Imexpharm Corp

For the last 8 years the compound annual growth rate for Imexpharm Corp's revenue is 10%. The projected CAGR for the next 1 year is 21%.

10%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Imexpharm Corp

For the last 8 years the compound annual growth rate for Imexpharm Corp's operating income is 16%. The projected CAGR for the next 1 year is 19%.

16%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Imexpharm Corp

For the last 8 years the compound annual growth rate for Imexpharm Corp's net income is 16%. The projected CAGR for the next 1 year is 26%.

16%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
IMP intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMP stock valuation using valuation multiples.
Wall Street Estimates
IMP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IMP's stock price target?
Price Target
46 308 VND

According to Wall Street analysts, the average 1-year price target for IMP is 46 308 VND with a low forecast of 45 248 VND and a high forecast of 48 300 VND.

What is Imexpharm Corp's Revenue forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Imexpharm Corp's revenue is 10%. The projected CAGR for the next 1 year is 21%.

What is Imexpharm Corp's Operating Income forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Imexpharm Corp's operating income is 16%. The projected CAGR for the next 1 year is 19%.

What is Imexpharm Corp's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Imexpharm Corp's net income is 16%. The projected CAGR for the next 1 year is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.